1620 Investment Advisors Inc. grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,680 shares of the company’s stock after purchasing an additional 187 shares during the period. 1620 Investment Advisors Inc.’s holdings in AstraZeneca were worth $755,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Able Wealth Management LLC acquired a new stake in shares of AstraZeneca during the fourth quarter worth $27,000. Pathway Financial Advisers LLC acquired a new stake in shares of AstraZeneca in the 1st quarter worth about $29,000. Pin Oak Investment Advisors Inc. increased its holdings in shares of AstraZeneca by 468.4% in the 4th quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after acquiring an additional 370 shares during the period. RFP Financial Group LLC increased its holdings in shares of AstraZeneca by 56.3% in the 1st quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock worth $33,000 after acquiring an additional 178 shares during the period. Finally, Northwest Financial Advisors acquired a new stake in shares of AstraZeneca in the 4th quarter worth about $34,000. 20.35% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Trading Up 0.4 %
AstraZeneca stock traded up $0.33 during trading hours on Thursday, reaching $85.89. 4,834,204 shares of the company’s stock traded hands, compared to its average volume of 5,325,271. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $86.04. The firm has a market capitalization of $266.30 billion, a price-to-earnings ratio of 42.10, a PEG ratio of 1.36 and a beta of 0.45. The firm’s 50 day moving average is $79.82 and its 200-day moving average is $73.86.
AstraZeneca Cuts Dividend
The company also recently announced a Semi-Annual dividend, which will be paid on Monday, September 9th. Investors of record on Friday, August 9th will be paid a $0.49 dividend. The ex-dividend date of this dividend is Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio is presently 48.04%.
Analysts Set New Price Targets
AZN has been the topic of a number of analyst reports. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. BMO Capital Markets increased their target price on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday, April 26th. The Goldman Sachs Group assumed coverage on shares of AstraZeneca in a research report on Thursday, May 30th. They issued a “buy” rating and a $97.00 target price for the company. TD Cowen increased their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Barclays upgraded shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $89.75.
Get Our Latest Analysis on AstraZeneca
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
- Five stocks we like better than AstraZeneca
- Retail Stocks Investing, Explained
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- What Are Dividend Champions? How to Invest in the Champions
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- What Investors Need to Know to Beat the Market
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.